Addex Therapeutics (ADXN) Capital Expenditures (2019 - 2024)
Addex Therapeutics (ADXN) posted Capital Expenditures of $1.5 billion for Q4 2024, down 77.13% sequentially from $6.4 billion in Q4 2023, and down 77.13% YoY from $6.4 billion in Q1 2024.
Addex Therapeutics (ADXN) Capital Expenditures (2019 - 2024) Analysis & Trends
Addex Therapeutics has reported Capital Expenditures for 6 years, with the latest figure at $1.5 billion in Q4 2024.
- Quarterly Capital Expenditures fell 77.13% year-over-year to $1.5 billion in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.5 billion (up 2017.52% YoY) and the FY2024 annual result came in at $1447.0, down 81.24% from the prior year.
- Capital Expenditures slipped to $1.5 billion in Q4 2024 per ADXN's latest filing, from $6.4 billion in the prior quarter.
- Over five years, Capital Expenditures peaked at $6.4 billion in Q4 2023 and troughed at -$5.5 billion in Q2 2023.
- A 5-year average of $101.7 million and a median of -$1818.8 in 2021 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 527315128.25% in 2023, down 127812814.85% in 2023.
- Over 5 years, Capital Expenditures stood at $78252.8 in 2020, then plunged by 46.49% to $41874.8 in 2021, then plunged by 97.12% to $1205.1 in 2022, then jumped by 527315128.25% to $6.4 billion in 2023, then slumped by 77.13% to $1.5 billion in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1.5 billion, $6.4 billion, and -$767.6 million for Q4 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.45 Bn |
| Dec 31, 2024 | 1.45 Bn |
| Dec 31, 2023 | 6.35 Bn |
| Dec 31, 2023 | 6.35 Bn |
| Sep 30, 2023 | -767.60 Mn |
| Sep 30, 2023 | -767.60 Mn |
| Jun 30, 2023 | -5.52 Bn |
| Jun 30, 2023 | -5.52 Bn |
| Mar 31, 2023 | -2,669.39 |
| Mar 31, 2023 | -2,669.39 |
| Dec 31, 2022 | 1,205.14 |
| Dec 31, 2022 | 1,205.14 |
| Sep 30, 2022 | -600.56 |
| Sep 30, 2022 | -600.56 |
| Dec 31, 2021 | 41,874.79 |
| Dec 31, 2021 | 41,874.79 |
| Sep 30, 2021 | -1,818.85 |
| Sep 30, 2021 | -1,818.85 |
| Jun 30, 2021 | -2,449.91 |
| Jun 30, 2021 | -2,449.91 |